Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 9/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | USP2 | O75604 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.54 |
| ▸ | TSHR | P16473 | 5/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20962696 | 0.94 | CYP2D6 (0.57) | CYP2D6MEN1KMT2AUSP2CYP3A4 | |
| SCHEMBL18389864 | 0.87 | CYP2D6 (0.64) | CYP2D6MEN1KMT2AUSP2CYP3A4 | |
| SCHEMBL18712904 | 0.85 | CYP2D6 (0.66) | CYP2D6MEN1KMT2AUSP2CYP3A4 | |
| SCHEMBL5243003 | 0.85 | CYP2D6 (0.67) | CYP2D6MEN1KMT2AUSP2CYP3A4 | |
| SCHEMBL18389865 | 0.84 | CYP2D6 (0.60) | CYP2D6MEN1KMT2AUSP2CYP3A4 | |
| SCHEMBL14218795 | 0.84 | CYP2D6 (0.60) | CYP2D6MEN1KMT2AUSP2CYP3A4 | |
| Hydrochloric Acid SCHEMBL9688641 | 0.83 | CYP2D6 (0.59) | CYP2D6MEN1KMT2AUSP2CYP3A4 | |
| SCHEMBL16349557 | 0.83 | CYP2D6 (0.59) | CYP2D6MEN1KMT2AUSP2CYP3A4 | |
| SCHEMBL18389859 | 0.82 | MC4R (0.62) | CYP2D6MEN1KMT2AUSP2CYP3A4 | |
| SCHEMBL6744977 | 0.81 | SIGMAR1 (0.72) | OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10023570-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170096425-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096425-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | CYP2D6 3133/4885MEN1 1015/4885KMT2A 1448/4885 |
| US-10023570-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | CYP2D6 3133/4885MEN1 1015/4885KMT2A 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.